Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : UTHR-a Promising Biotech in the works here? -- Ignore unavailable to you. Want to Upgrade?

To: LzzrdKing who wrote (23)	8/23/1999 10:02:00 PM
From: kendall harmon	Respond to of 66

UTHR--I spoke with Therese Fargo in investor relations today. She is working on getting me the information I requested. Although UTHR is presenting a paper at the conference in Barcelona, they are not the organizers of the conference. They will be getting me more information in a little while.

To: LzzrdKing who wrote (23)	8/23/1999 11:37:00 PM
From: kendall harmon	Respond to of 66

UTHR-If anyone can by any chance track down the ag edwards report I would be grateful to hear from it or see it Princeton, New Jersey, July 19 (Bloomberg Data) -- United Therapeutics Corp. (UTHR US) was rated ''buy'' in new coverage by analyst Kenneth R. Nover at A.G. Edwards & Sons Inc. The 12-month target price is $30.00 per share.

To: LzzrdKing who wrote (23)	8/25/1999 6:29:00 AM
From: kendall harmon	Respond to of 66

UTHR Phase II results--A simple way to consider the potential impact of the Barcelona paper next week is to look at the action in BCRX yesterday. BCRX had positive phase II results on their product which will treat flu: cbs.marketwatch.com. UTHR will be presenting its phase II results for its product which treats pulmonary hypertension. Now we could have a debate about which is a potential bigger market, etc., but the point is that phase II results are potentially important events for biotechnology stocks.